XTX Topco Ltd Makes New $524,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)

XTX Topco Ltd purchased a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,249 shares of the biopharmaceutical company’s stock, valued at approximately $524,000. XTX Topco Ltd owned approximately 0.08% of Sage Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Bellevue Group AG lifted its position in Sage Therapeutics by 27.1% in the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock valued at $83,684,000 after acquiring an additional 952,193 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Sage Therapeutics in the second quarter valued at about $7,281,000. Renaissance Technologies LLC boosted its position in shares of Sage Therapeutics by 1,476.6% during the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock worth $6,010,000 after buying an additional 518,296 shares during the period. Vanguard Group Inc. grew its holdings in shares of Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after buying an additional 432,013 shares in the last quarter. Finally, Baker BROS. Advisors LP acquired a new stake in Sage Therapeutics in the 1st quarter valued at approximately $7,631,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SAGE. Scotiabank decreased their price target on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 6th. Citigroup assumed coverage on shares of Sage Therapeutics in a research note on Wednesday, May 29th. They set a “sell” rating and a $8.00 price objective for the company. Baird R W raised Sage Therapeutics to a “hold” rating in a research report on Wednesday, May 29th. Finally, Truist Financial reduced their price target on Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating for the company in a research report on Wednesday, August 14th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Sage Therapeutics currently has an average rating of “Hold” and a consensus target price of $16.06.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $7.31 on Wednesday. The firm has a market cap of $439.93 million, a price-to-earnings ratio of -0.87 and a beta of 0.91. The stock’s fifty day moving average price is $8.83 and its two-hundred day moving average price is $11.97. Sage Therapeutics, Inc. has a one year low of $7.10 and a one year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.02). The business had revenue of $8.65 million for the quarter, compared to the consensus estimate of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. Sage Therapeutics’s revenue was up 249.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.68) earnings per share. On average, equities analysts anticipate that Sage Therapeutics, Inc. will post -6.47 earnings per share for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.